Doctors Welcome Hepatitis C Drug Rivals, Gilead Sciences, Inc. Still Leads

Published: Apr 11, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

Gilead, under fire from insurers and legislators for the $1,000-a-pill price of its Sovaldi drug, presented pivotal data on Friday at the European Association for the Study of the Liver conference in London, showing a cure rate of 94 percent after eight weeks of treatment with its experimental two-drug pill.

Help employers find you! Check out all the jobs and post your resume.

Back to news